Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma SS Neelapu, FL Locke, NL Bartlett, LJ Lekakis, DB Miklos, CA Jacobson, ... New England Journal of Medicine 377 (26), 2531-2544, 2017 | 5123 | 2017 |
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial FL Locke, A Ghobadi, CA Jacobson, DB Miklos, LJ Lekakis, OO Oluwole, ... The lancet oncology 20 (1), 31-42, 2019 | 2028 | 2019 |
KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma M Wang, J Munoz, A Goy, FL Locke, CA Jacobson, BT Hill, ... New England journal of medicine 382 (14), 1331-1342, 2020 | 1491 | 2020 |
B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies DA Winer, S Winer, L Shen, PP Wadia, J Yantha, G Paltser, H Tsui, P Wu, ... Nature medicine 17 (5), 610-617, 2011 | 1195 | 2011 |
Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma FL Locke, DB Miklos, CA Jacobson, MA Perales, MJ Kersten, OO Oluwole, ... New England Journal of Medicine 386 (7), 640-654, 2022 | 972 | 2022 |
Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium LJ Nastoupil, MD Jain, L Feng, JY Spiegel, A Ghobadi, YI Lin, S Dahiya, ... Journal of Clinical Oncology 38 (27), 3119-3128, 2020 | 643 | 2020 |
Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing SD Boyd, EL Marshall, JD Merker, JM Maniar, LN Zhang, B Sahaf, ... Science translational medicine 1 (12), 12ra23-12ra23, 2009 | 581 | 2009 |
Rituximab for steroid-refractory chronic graft-versus-host disease C Cutler, D Miklos, HT Kim, N Treister, SB Woo, D Bienfang, LB Klickstein, ... Blood 108 (2), 756-762, 2006 | 514 | 2006 |
Antibody responses to HY minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission DB Miklos, HT Kim, KH Miller, L Guo, E Zorn, SJ Lee, EP Hochberg, ... Blood 105 (7), 2973-2978, 2005 | 497 | 2005 |
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy D Miklos, CS Cutler, M Arora, EK Waller, M Jagasia, I Pusic, ME Flowers, ... Blood, The Journal of the American Society of Hematology 130 (21), 2243-2250, 2017 | 464 | 2017 |
The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in … KR Cooke, L Luznik, S Sarantopoulos, FT Hakim, M Jagasia, DH Fowler, ... Biology of Blood and Marrow Transplantation 23 (2), 211-234, 2017 | 454 | 2017 |
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial JY Spiegel, S Patel, L Muffly, NM Hossain, J Oak, JH Baird, MJ Frank, ... Nature medicine 27 (8), 1419-1431, 2021 | 404 | 2021 |
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing DM Kurtz, MR Green, SV Bratman, F Scherer, CL Liu, CA Kunder, ... Blood, The Journal of the American Society of Hematology 125 (24), 3679-3687, 2015 | 353 | 2015 |
Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements SD Boyd, BA Gaëta, KJ Jackson, AZ Fire, EL Marshall, JD Merker, ... The Journal of Immunology 184 (12), 6986-6992, 2010 | 351 | 2010 |
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma FL Locke, JM Rossi, SS Neelapu, CA Jacobson, DB Miklos, A Ghobadi, ... Blood advances 4 (19), 4898-4911, 2020 | 308 | 2020 |
High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment AC Logan, H Gao, C Wang, B Sahaf, CD Jones, EL Marshall, I Buño, ... Proceedings of the National Academy of Sciences 108 (52), 21194-21199, 2011 | 245 | 2011 |
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation JH Antin, HT Kim, C Cutler, VT Ho, SJ Lee, DB Miklos, EP Hochberg, ... Blood 102 (5), 1601-1605, 2003 | 217 | 2003 |
Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation E Zorn, DB Miklos, BH Floyd, A Mattes-Ritz, L Guo, RJ Soiffer, JH Antin, ... The Journal of experimental medicine 199 (8), 1133-1142, 2004 | 211 | 2004 |
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated … HE Kohrt, BB Turnbull, K Heydari, JA Shizuru, GG Laport, DB Miklos, ... Blood, The Journal of the American Society of Hematology 114 (5), 1099-1109, 2009 | 195 | 2009 |
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus … KR Schultz, DB Miklos, D Fowler, K Cooke, J Shizuru, E Zorn, E Holler, ... Biology of Blood and Marrow Transplantation 12 (2), 126-137, 2006 | 189 | 2006 |